The radiation oncology subspecialists at the OSUCCC – James translate leading-edge clinical and translational research into science-based, personalized care tailored to the unique biological characteristics of each patient’s cancer.
Although cancers may come from the same tissue type (e.g., breast, lung, prostate) and appear similar under the microscope, more and more evidence shows that they have significant molecular and genetic differences for each cancer patient. This means that a treatment that is effective for one patient may be ineffective for another.
As members of the Department of Radiation Oncology at Ohio State’s College of Medicine, our physician experts conduct basic research and clinical trials to determine the most effective treatments for each patient. They strive to bring discoveries into clinical cancer care by ensuring that a wide range of clinical trials are available to patients with cancer anywhere in the body, including breast, central nervous system, gastrointestinal, genitourinary, gynecologic, head and neck, thoracic, leukemia and lymphoma, melanoma and other skin cancers, and sarcoma.
For example, an internationally recognized research team at the OSUCCC – James identified a possible new target for future drugs to treat glioblastoma multiforme (GBM), the most frequent and lethal form of brain cancer. The findings, published in the journal Cancer Research, show that high levels of an enzyme called PRMT5 are associated with aggressive growth of GBM, which strikes nearly 14,000 Americans annually and has an average survival period of only 15 months following surgery, chemotherapy and radiation treatment. But the OSUCCC – James research team’s study showed that blocking the PRMT5 enzyme inhibited the growth, proliferation and spread of GBM cells and improved survival in a laboratory animal model — providing a rationale for developing agents that target PRMT5 in humans with this disease.
Other successes for these world-renowned radiation oncology experts include:
- Designing the first-of-a-kind prone board for breast cancer patients to prevent cardio-toxicity (with patent pending).
- Being the first radiation oncology investigators to patent a novel predictive biomarker panel for anti-epidermal growth factor therapies when combined with radiation for newly diagnosed Glioblastoma.
- Being the first radiation oncology investigators develop a novel predictive biomarker model for salvage radiation after radical prostatectomy (with patent pending).
- A brand new Radiation Oncology Center located on the second floor of the new James Cancer Hospital – the only completely above-ground radiation center in the country, offering generous amounts of natural light to assist with patient healing and comfort.
- Housing the first Varian TrueBeam site in Ohio and one of the first in the entire country.
- Receiving a $100 million Health and Human Services Grant (the largest grant in history for the field of radiation oncology) for additional study and research in radiation oncology treatments for cancer patients.
- Receiving more that $25 million in research funding for the federal government’s National Institutes of Health projects.
Findings from research published in numerous respected national and international publications, including: Radiation Oncology, New England Journal of Medicine, Journal of the American Medical Association, Clinical Cancer Research, Journal of the National Cancer Institute, and many more.
Radiation Oncology Clinical Trials
For cancer patients, research and clinical trials mean hope.
Clinical trials are research studies designed to test new, innovative ways to prevent, detect, diagnose or treat cancer patients.
The OSUCCC – James has hundreds of open clinical trials at any given time, with some of the world’s latest discoveries available to clinical trial patients right here in Columbus, Ohio. In fact, patients have access to more cancer clinical trials here than at nearly any other hospital in the region, as well as access to some of the most advanced, targeted treatments and drugs available.
Patients can enter clinical trials before, during or after starting their individual treatments. They are closely monitored by the OSUCCC – James specialists.
The OSUCCC – James is one of only four U.S. cancer centers funded by the National Cancer Institute (NCI) to conduct phase I and phase II clinical trials on novel anticancer research. These trials go only to centers that demonstrate an exemplary capacity for research and clinical care, the expertise to deliver the latest in treatments, and the infrastructure to interpret and track treatment results.
If you have been diagnosed with cancer and would like a second opinion, or if you would like to speak with a cancer specialist, please call The James Line at 800-293-5066 or 614-293-5066 to make an appointment.